Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Multicenter Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Tolerability of BCD-033 (CJSC BIOCAD, Russia) and Rebif (Merck Serono S.p.A, Italy) After Single Subcutaneous Administration to Healthy Volunteers

Next Previous
X
Search
Trial Profile

International Multicenter Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Tolerability of BCD-033 (CJSC BIOCAD, Russia) and Rebif (Merck Serono S.p.A, Italy) After Single Subcutaneous Administration to Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 May 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy; Colorectal cancer; Crohn's disease; Glioma; Hepatitis B; Hepatitis C; Human papillomavirus infections; Multiple sclerosis; Neurological disorders; Non-small cell lung cancer; Pulmonary fibrosis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Biocad

    • Most Recent Events

    • 10 Jan 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov
    • 24 Jan 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top